Biocon Q2FY27 Revenue ₹4,389 Cr, Net Profit ₹41 Cr

Biocon Limited announced its unaudited consolidated financial results for Q2FY27, reporting a total income of ₹4,423 crore, a 1% increase year-on-year. Consolidated operating revenue grew 2% YoY to ₹4,389 crore. Biopharma revenue increased 5% YoY to ₹3,583 crore, with Biosimilars up 3% to ₹2,809 crore and Generics up 10% to ₹774 crore. Services revenue saw a 13% sequential increase to ₹833 crore. Consolidated EBITDA stood at ₹865 crore, a 7% decrease YoY. Net Profit before exceptional items was ₹44 crore, and reported Net Profit was ₹41 crore, both down 52% YoY. Key highlights include a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at approximately USD 400 million and progress in biosimilar innovation with EMA recommendations.